| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung CancerNCT04892472 | NovoCure GmbH | Phase 2 | Terminated | 2025-01-10Actual |
| CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin SyndromeNCT04893486 | PVLA | Phase 2 | Completed | 2023-03-13Actual |
| A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric ParticipantsNCT04903288 | PTC Therapeutics | Phase 2 | Active not recruiting | 2023-05-22Actual |
| Trial of AD113 and Atomoxetine in OSA Patients With HypertensionNCT04905979 | Apnimed | Phase 2 | Completed | 2023-01-31Actual |
| Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT04906421 | SGMT | Phase 2 | Completed | 2023-10-02Actual |
| INM-755 (Cannabinol) Cream for Treatment of Epidermolysis BullosaNCT04908215 | INM | Phase 2 | Completed | 2023-04-03Actual |
| A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque PsoriasisNCT04908514 | ALDX | Phase 2 | Completed | 2022-01-21Actual |
| An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEENCT04912856 | XENE | Phase 3 | Terminated | 2023-11-17Actual |
| Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.NCT04913675 | VIR | Phase 3 | Terminated | 2022-07-19Actual |
| A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaNCT04917874 | KRYS | Phase 3 | Completed | 2023-07-31Actual |
| Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCNCT04919811 | NUVB | Phase 2 | Active not recruiting | 2025-06-11Actual |
| Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.NCT04925024 | LGVN | Phase 2 | Active not recruiting | 2026-06-30Estimated |
| A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224NCT04932512 | IONS | Phase 2 | Completed | 2024-01-10Actual |
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesNCT04933721 | BioCryst Pharmaceuticals | Phase 3 | Enrolling by invitation | 2031-08Estimated |
| A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT04944784 | Cytokinetics | Phase 3 | Terminated | 2023-07-18Actual |
| A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT04947553 | AXSM | Phase 3 | Completed | 2024-12-03Actual |
| Study of INBRX-109 in Conventional ChondrosarcomaNCT04950075 | INBX | Phase 2 | Active not recruiting | 2025-09-30Actual |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)NCT04951219 | MDGL | Phase 3 | Active not recruiting | 2027-03Estimated |
| Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSNCT04957485 | SIGA Technologies | Phase 2 | Active not recruiting | 2027-01-01Estimated |
| DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayNCT04963231 | RYTM | Phase 2 | Completed | 2023-08-04Actual |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)NCT04964089 | KOD | Phase 3 | Completed | 2023-03-28Actual |
| Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityNCT04966741 | RYTM | Phase 3 | Completed | 2023-09-18Actual |
| A Clinical Trial to Assess Subjects With Dry Eye Disease.NCT04971031 | ALDX | Phase 2 | Completed | 2021-09-08Actual |
| Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysNCT04971109 | SIGA Technologies | Phase 3 | Completed | 2023-05-12Actual |
| Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)NCT04973228 | ARQT | Phase 3 | Completed | 2022-04-06Actual |
| Afrezza® INHALE-1 Study in PediatricsNCT04974528 | Mannkind Corporation | Phase 3 | Completed | 2024-10-03Actual |
| Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionNCT04980482 | Arbutus Biopharma Corporation | Phase 2 | Completed | 2025-03-13Actual |
| Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisNCT04984278 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2022-11-11Actual |
| Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsNCT04987229 | Alkermes, Inc. | Phase 3 | Enrolling by invitation | 2027-09Estimated |
| An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeNCT04988867 | ACAD | Phase 2, Phase 3 | Terminated | 2023-05-31Actual |
Trial details
- Registry ID
- NCT04892472
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04893486
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04903288
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04905979
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04906421
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04908215
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04908514
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04912856
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04913675
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04917874
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04919811
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04925024
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04932512
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04933721
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04944784
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04947553
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04950075
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04951219
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04957485
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04963231
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04964089
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04966741
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04971031
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04971109
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04973228
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04974528
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04980482
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04984278
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04987229
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04988867
- Phase
- Phase 2, Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.